The Joe Rogan ExperienceJoe Rogan Experience #1136 - Hamilton Morris
CHAPTERS
Back on the mic—why long-form conversation works (and why they’re sober now)
Joe and Hamilton open by contrasting this episode with their heavily stoned podcast from seven years earlier. They reflect on how the show grew and why long-form dialogue allows nuance that TV and panel formats routinely destroy.
TV talk-show chaos: Dr. Oz, applause signs, and fake ‘debate’ formats
Hamilton explains why talk shows create unnatural conversations designed for applause and conflict, using his Dr. Oz experience as an example. Joe agrees that studio audiences and cue-card reactions distort what should be a real exchange.
Kratom deep dive: dosing, risks, and why people use it to quit opioids
The conversation pivots to kratom—Joe is actively taking it for knee pain—and they explore its dosing, effects, and safety claims. Hamilton argues it’s an opioid-like drug that can still be useful, especially for reducing reliance on more dangerous opioids.
Freedom vs ‘safety’: the case for cognitive liberty and honest education
Hamilton and Joe argue that drug policy shouldn’t hinge solely on proving perfect safety. They stress adult autonomy, realistic risk education, and the dangers of exaggeration—especially when it undermines trust about truly dangerous drugs.
The opioid epidemic narrative: pharma scapegoating, addiction realities, and off-ramps
Hamilton critiques simplistic media coverage that treats opioid addiction as a shocking corporate discovery rather than longstanding pharmacology. Joe emphasizes the need for responsible protocols to taper off opioids after medical use.
Pharmacological determinism is a myth: culture, context, and drug stereotypes (PCP, heroin, etc.)
Hamilton challenges the idea that each drug has a fixed, inevitable behavioral outcome. He uses cross-cultural examples and PCP’s medical history to show how expectations and social narratives shape experiences and outcomes.
Schedules, prohibition, and capitalism: how drugs become legal (and who profits)
They discuss how drug scheduling undermines public trust and blocks medical research, while legalization often advances through corporate lobbying rather than counterculture activism. Both note the moral and practical tension: progress happens, but often via money and power.
Cannabis psychology: shame, paranoia memes, and reframing ‘bad trips’
Hamilton argues that cultural narratives—paranoia, bad trips, stigma—can become self-fulfilling. He reframes difficult psychedelic experiences as potentially the most instructive, while Joe notes genuine risk for psychosis-prone individuals.
Research needs vs political science: predicting risk, genetics, and mechanism-level understanding
They distinguish between politically motivated trials (proving already-suspected benefits) and deeper mechanistic research that could predict individual risk. Both want more nuanced studies—diet, receptor subtypes, genetics—to understand who benefits and who shouldn’t use what.
Media incentives and drug panic: sensationalism, synthetic cannabinoids, and the cost of headlines
Hamilton explains how journalists and editors amplify fear because outrage and clicks pay. He argues that demonizing “synthetic” drugs is often misguided and can sabotage future medical discoveries by driving scheduling bans based on panic, not evidence.
Stimulants and moral narratives: Adderall, meth, and the urge to blame drugs for people
They discuss how amphetamine stories repeat across decades and why “one carbon away from meth” rhetoric is simplistic. Hamilton pushes back on using drugs as convenient explanations for complex behavior (Trump/Hitler/Bourdain/Columbine framing).
Fentanyl and synthetic cannabinoid lessons: economics, unintended outcomes, and new syndromes
Hamilton argues fentanyl’s catastrophe is largely about black-market economics, lack of safer supply, and poor education, not the molecule being inherently ‘evil.’ They also explore what synthetic cannabinoids unexpectedly taught medicine—like cannabinoid hyperemesis mechanisms and lethal potential at high potency.
Scheduling blocks discovery: obscure psychedelics, lab bureaucracy, and ibogaine’s huge potential
They detail how compounds get scheduled with minimal opposition, chilling the very scientists who could study them. Ibogaine becomes the flagship example: complex pharmacology, promise for addiction and Parkinson’s, but hampered by Schedule I restrictions and burdensome oversight.
Toad venom, DMT myths, and what ‘ancient use’ claims get wrong
Hamilton traces how 5-MeO-DMT toad-venom practice lacks strong ancient evidence and corrects the popular ‘lick the toad’ myth. They then explore the practical chemistry of DMT extraction and why biblical “burning bush” theories are chemically and historically speculative.
Endogenous altered states: DMT debates, breathwork, and walking psychedelics in NYC
They debate what it would mean even if DMT were produced in the brain, noting alternative endogenous systems (kappa-opioid ligands, CO₂ effects). Hamilton contrasts breathwork/Kundalini with psychedelics’ unique ability to induce altered states while moving through everyday life, using New York as his example.
Mescaline plants and conservation: peyote’s harsh beauty, slow growth, and San Pedro as an alternative
Hamilton describes peyote’s history (including the Native American Church), its intense nausea and long duration, and serious sustainability concerns due to slow growth and habitat loss. They compare it with San Pedro, which grows faster and can be prepared in lower-potency traditional brews.
Ambien, disinhibition, and ‘drug explanations’ for public behavior (Roseanne, racism, and brain injury)
Joe raises Roseanne Barr’s Ambien claim, arguing the public wants a villain rather than a complicated pharmacological explanation. Hamilton outlines Ambien’s well-documented bizarre behaviors, shares personal stories of severe disinhibition, and notes surprising research like propranolol reducing implicit bias and Ambien temporarily reviving function in brain-injured patients.
Amanita muscaria, muscimol-class psychedelia, and the ‘lost technology’ question
They examine why Amanita muscaria is culturally iconic yet often unpleasant or toxic in practice, and why isolated muscimol would be preferable. Hamilton connects it to pharmaceutical muscimol-derivatives (like gaboxadol) that can produce powerful, unfamiliar psychedelic-dream states and raises the broader idea that plant chemistry evolves and human use may have shaped what survives.
